EDNRA and breast carcinoma: All the five pair-matched patients had SPARC/Endothelin 1/ETAR (+++) in dysplastic lesions; as shown in Patients 1–3, the strong signal of SPARC remained persistently elevated in breast carcinoma cells as well as in bone metastasis cells and stroma, while the other two pair-matched patients had a lower staining of SPARC (+) in the carcinoma cells (data not shown).